In 2023, the sales of Renin-Angiotensin System (RAS) medicines in Chile stood at 91.45 billion Chilean Pesos. The forecasted data for the following years indicate a steady increase: 97.14 billion in 2024, 103.11 billion in 2025, 109.03 billion in 2026, 114.89 billion in 2027, and 120.69 billion in 2028. The year-on-year growth rate from 2023 to 2024 is approximately 6.21%, followed by 6.2% from 2024 to 2025, 5.75% from 2025 to 2026, 5.38% from 2026 to 2027, and 5.05% from 2027 to 2028. The compound annual growth rate (CAGR) over the five-year period 2023-2028 is around 5.72%.
Future trends to watch include potential regulatory changes, advances in RAS-related medical research, and demographic shifts, particularly an aging population that may increase the demand for hypertension and cardiovascular treatments. Moreover, monitoring competitive dynamics and market entries by new pharmaceutical players could also impact future sales trajectories.
